Navigation Links
Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing

ALLENDALE, N.J., Jan. 12, 2012 /PRNewswire/ -- NeoStem's cell therapy manufacturing division, Progenitor Cell Therapy ("PCT"), a NeoStem, Inc. company (NYSE Amex: NBS) ("NeoStem" or the "Company"), announced today an agreement whereby PCT will provide contract manufacturing and regulatory services related to the development of Islet Sciences – PTM, which will be an injectable suspension of microencapsulated insulin-producing, pancreatic islet cells which are harvested from designated pathogen free pigs. As part of this arrangement, PCT will perform microencapsulation for parsing beta pancreatic islets for xenotransplantation using piglet pancreata. Islet Sciences, Inc. ("Islet") is a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes and is a wholly-owned subsidiary of One E-Commerce Corporation (OTCBB: ONCE). 

A 2010 study by the CDC found that approximately 25.8 million Americans, more than 8% of the population, were affected by diabetes. 5% of this number, approximately 1.3 million, have type 1 diabetes. Type 1 diabetes is estimated to cost the US $14.4 billion total annually.

"Given the robust market opportunity and the potential for cell therapy to alter the disease paradigm, NeoStem has agreed to this novel arrangement whereby PCT will subsidize manufacturing margin related to current services for Islet Sciences – PTM product in exchange for royalties on future sales, exclusive manufacturing rights for both clinical trial and commercial manufacturing and an equity stake in Islet's parent. We recognize that PCT's track record of developing cell therapies cost efficiently for cell therapy companies makes this a truly compelling opportunity in the industry," said John Steel, CEO of Islet Sciences.

"Our team looks forward to applying its process and assay expertise, in partnership with the scientific expertise of Dr. Jonathan Lakey, scientific advisor to Islet, and his team, towards the development of this novel and creative cellular therapeutic for the treatment of type 1 diabetes," said Robert A. Preti, PhD, President of PCT. "We are honored that Islet Sciences has enlisted PCT to provide manufacturing and development support as it advances this important product through clinical development."Dr. Robin L. Smith, Chairman and CEO of NeoStem, added, "We are excited to begin using our manufacturing currency at PCT to support important technologies with promise by providing manufacturing and regulatory support at a reduced profit margin in exchange for participation in future royalties, equity as well as a commitment for clinical trial and commercial manufacturing exclusivity."

About Type 1 DiabetesAccording to the American Diabetes Association, type 1 diabetes, previously called insulin-dependent diabetes mellitus (IDDM) or juvenile diabetes, is an autoimmune disease characterized by insulin deficiency resulting from destruction of beta-cells in the pancreas, ultimately resulting in the body's inability to convert consumed sugar and starches into energy. This form of diabetes usually affects children and young adults, but it can occur at any age. Although insulin therapy and other treatments can be used to manage the condition, the condition is currently incurable.  

About NeoStem, Inc.NeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, Inc., also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and  has commenced enrollment in a Phase 2 trial for the preservation of heart function after a heart attack.  Amorcyte expects to begin a Phase 1 clinical trial in 2012 for AMR-001 for the treatment of patients with congestive heart failure. Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with its partner Becton-Dickinson.  NeoStem's pre-clinical assets include its VSEL™ Technology platform for regenerative medicine, which NeoStem believes to be an endogenous, pluripotent, non-embryonic stem cell that has the potential to change the paradigm of cell therapy as we know it today.

For more information on NeoStem, please visit

About Islet Sciences, Inc.Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes. Islet's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. Islet's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements for NeoStem, PCT and Islet Sciences reflect their respective managements' current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the companies' successful execution of their  respective business strategies, including with respect to the successful development of cell therapeutics, including with respect to Islet Sciences – PTM, as well as the future of the cell therapeutics industry. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements for NeoStem and PCT include the "Risk Factors" described in NeoStem's prospectus supplement filed with the Securities and Exchange Commission ("SEC") on September 30, 2011 and for Islet include the risks described in the One E-Commerce Corporation Form 8-K filed with the Securities and Exchange Commission on December 30, 2011. The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.For more information, please contact:


 Trout Group

NeoStem, Inc. Gitanjali Jain Ogawa, Vice President

Robin Smith, CEO Phone: +1-646-378-2949

Phone: +1-212-584-4174 Email:



SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
2. Pigs to Be Genotyped to Improve Selection and Breeding for Pancreatic Islet Cell Research
3. Beta-Pro Donates Human Islet Cells to Diabetes Researcher
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Milestone Biosciences, LLC Further Strengthens Executive Management Team
6. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
7. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
8. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
9. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
10. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
11. Pressure BioSciences, Inc. Provides Corporate Update
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, today announced ... meetings taking place in the month of October: ... Forum RepliCel will be presenting at the annual ... the Mesa to be held October 7-9 in ...
(Date:10/8/2015)... TORONTO, CANADA (PRWEB) , ... October 08, 2015 ... ... it has entered into an exclusive license agreement to develop and commercialize intellectual ... expands upon the original agreement from February 2009, and affords exclusive worldwide rights ...
(Date:10/7/2015)... ... 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal ... Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the ... He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute ...
(Date:10/7/2015)...   PDI , a leader in infection prevention ... key challenges across various healthcare settings, as well as ... This tool is part of a larger effort to ... efficiencies and lower healthcare-associated infections. ... of how to use the right product, in the ...
Breaking Biology Technology:
... JOLLA, Calif., Oct. 20, 2011 Regulus Therapeutics ... development of innovative medicines targeting microRNAs, and collaborators at ... Center today announced the publication of new pre-clinical research ... et al., Nature , October 20, 2011). ...
... cell carcinomas are amongst the most frequent cancers in ... like many other human cancers, contain particular cancer cells, ... potential that sustain tumor growth. Little is known about ... High level of VEGF expression in skin cancer ...
... Researchers at Purdue University and the National Institute of ... enough to fit on a computer chip that converts ... that might have applications in more advanced sensors, communications ... very high rates, corresponding to hundreds of billions of ...
Cached Biology Technology:
(Date:10/9/2015)... 09 2015 ... the "Samsung Galaxy S6 Fingerprint Sensor ... their offering. --> ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> Research and Markets ( ...
(Date:10/8/2015)... Oct. 8, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial ... on Thursday, October 22, 2015, after the close ... conference call for analysts and investors at 2:00 ... may discuss forward-looking information. ...
(Date:10/8/2015)... SALT LAKE CITY , 8. Oktober ... (OTCQX: TRCK), ein global tätiges Unternehmen des ... man einem Vertrag mit der Gefängnisbehörde Virginias ... in dessen Rahmen elektronische Überwachungsdienste für alle ... Derek Cassell , Präsident für ...
Breaking Biology News(10 mins):
... popular with consumers who like the convenience and ... table grapes fresh and increase shelf life, scientists ... alternatives to conventional packing methods. Researchers from the ... ARS) have developed and tested an effective new ...
... OHLoblolly pine bark is the primary component of nursery ... shortage of the widely used organic material is prompting ... recent study by James E. Altland and Charles Krause ... Agricultural Research and Development Center was designed to determine ...
... within patient records or detailed in newspaper clippings can ... the discovery of trends that were previously overlooked, according ... interactive maps and graphs, combined with word search interfaces, ... the spread of Swine flu," said Frank Hardisty, research ...
Cached Biology News:
Human IL-19 MAb (Clone 152112)...
geminin, DNA replication inhibitor...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Human IL-17D Affinity Purified Polyclonal Ab...
Biology Products: